Jones Financial Companies Lllp Has $229,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Jones Financial Companies Lllp lifted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 397.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 33,817 shares of the company’s stock after purchasing an additional 27,016 shares during the period. Jones Financial Companies Lllp’s holdings in Recursion Pharmaceuticals were worth $229,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in RXRX. Decker Retirement Planning Inc. bought a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth $26,000. Private Trust Co. NA bought a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth $27,000. GAMMA Investing LLC grew its holdings in shares of Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after acquiring an additional 4,091 shares during the last quarter. Finally, KBC Group NV boosted its holdings in Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after acquiring an additional 3,377 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on RXRX. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. KeyCorp decreased their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Leerink Partners decreased their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, February 28th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Trading Down 3.7 %

NASDAQ:RXRX opened at $5.94 on Friday. Recursion Pharmaceuticals, Inc. has a 1-year low of $5.60 and a 1-year high of $12.36. The business’s 50-day moving average price is $7.57 and its two-hundred day moving average price is $7.03. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $2.39 billion, a price-to-earnings ratio of -3.88 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The company had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company’s quarterly revenue was down 57.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.42) EPS. On average, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.